search
Back to results

The Programmed Intermittent Epidural Bolus Adrenaline Study (PIEBA)

Primary Purpose

Labor Pain

Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Continuous epidural infusion
Intermittent epidural bolus
Sponsored by
University Hospital, Akershus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Labor Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Pregnant women in labor requesting epidural analgesia
  • ASA group 1 and 2
  • 0 or 1 previous births
  • Must be at least 18 years of age.
  • Singleton pregnancy
  • Active labor
  • Signed informed consent and expected cooperation of the patient

Exclusion Criteria:

  • Poor communication skills in norwegian or english
  • Adverse reactions to local anesthetics or synthetic opioids
  • Body height below 150 cm
  • Gestational age below 37 weeks, 0 days
  • Any contraindication to epidural catheter placement (e.g. patients with coagulopathy, infection in area etc)
  • Pre-eclampsia
  • Sound reason by the investigator to suspect patient non-compliance (e.g. with use of PCEA)

Sites / Locations

  • Akershus UH

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intermittent epidural bolus (IEB)

Continuous epidural infusion (CEI)

Arm Description

Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.

Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.

Outcomes

Primary Outcome Measures

Cumulative drug consumption, time adjusted
Cumulative drug consumption is assessed at the end of treatment (at birth). The total dose is adjusted for differences in treatment time and other possible factors of influence (BMI, parity, age, gestational age etc.)

Secondary Outcome Measures

Maternal satisfaction with treatment
Overall satisfaction with treatment will be assessed the day after end of treatment on a 0-10 scale.
Mode of delivery
Mode of delivery will be assessed and categorized as vaginal,instrumentally assisted or cesarean delivery.
Motor block
Extent of lower extremity motor block will be assessed using a modified Bromage score
Anesthesiologic intervention
The need for additional anesthesiologic intervention, including time to this intervention from start of treatment.
Incidence of expected adverse events
Expected adverse events include hypotension (systolic blood pressure < 90 mmHg and/or use of vasopressors), nausea (mild/moderate/severe) and pruritus (mild/moderate/severe).
Pain rating
Pain rating will be assessed using a numeric rating scale (NRS, 0-10; 0= no pain, 10=worst imaginable pain) before treatment start, at every hour for the first 8 hours of treatment and every other hour thereafter. Worst pain at delivery will also be assessed.

Full Information

First Posted
January 31, 2017
Last Updated
September 18, 2018
Sponsor
University Hospital, Akershus
search

1. Study Identification

Unique Protocol Identification Number
NCT03043781
Brief Title
The Programmed Intermittent Epidural Bolus Adrenaline Study
Acronym
PIEBA
Official Title
The Programmed Intermittent Epidural Bolus Adrenaline Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2018
Overall Recruitment Status
Completed
Study Start Date
March 20, 2017 (Actual)
Primary Completion Date
September 5, 2018 (Actual)
Study Completion Date
September 5, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Akershus

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the use of intermittent epidural boluses compared to continuous infusion in maintaining epidural pain relief in labor. The medicine solution used contains, in addition to bupivacain and fentanyl, adrenalin in both groups.
Detailed Description
Labor is often painful for the woman going through it, and thus many women choose to have pain relief by an epidural catheter. This is done by placing a thin plastic catheter in the epidural space in the lower back of the patient, and injecting a medicine solution usually consisting of local anesthesia and opioids. To ensure an effective pain relief through the labor process, additional medicine solution is injected through the catheter. Traditionally, this is done by a continuous infusion, often with the addition of patient controlled boluses. In this study the investigators investigate if maintaining the pain relief through programmed hourly intermittent boluses is more effective than continuous infusion. This is done in other studies with promising results, but the difference in this study is the addition of adrenaline to the medicine solution in order to make it more effective.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Labor Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
150 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intermittent epidural bolus (IEB)
Arm Type
Experimental
Arm Description
Bolus of 5 ml every hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
Arm Title
Continuous epidural infusion (CEI)
Arm Type
Active Comparator
Arm Description
Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
Intervention Type
Other
Intervention Name(s)
Continuous epidural infusion
Intervention Description
Continuous infusion, 5 ml/h
Intervention Type
Other
Intervention Name(s)
Intermittent epidural bolus
Intervention Description
Intermittent bolus 5 ml every hour
Primary Outcome Measure Information:
Title
Cumulative drug consumption, time adjusted
Description
Cumulative drug consumption is assessed at the end of treatment (at birth). The total dose is adjusted for differences in treatment time and other possible factors of influence (BMI, parity, age, gestational age etc.)
Time Frame
One assessment, within 24 hours of end of treatment
Secondary Outcome Measure Information:
Title
Maternal satisfaction with treatment
Description
Overall satisfaction with treatment will be assessed the day after end of treatment on a 0-10 scale.
Time Frame
One assessment, within 24 hours of end of treatment
Title
Mode of delivery
Description
Mode of delivery will be assessed and categorized as vaginal,instrumentally assisted or cesarean delivery.
Time Frame
One assessment, within 24 hours of end of treatment
Title
Motor block
Description
Extent of lower extremity motor block will be assessed using a modified Bromage score
Time Frame
One assessment at one hour after treatment initiation and one at 10 cm cervical dilatation.
Title
Anesthesiologic intervention
Description
The need for additional anesthesiologic intervention, including time to this intervention from start of treatment.
Time Frame
During treatment (0-24 hours)
Title
Incidence of expected adverse events
Description
Expected adverse events include hypotension (systolic blood pressure < 90 mmHg and/or use of vasopressors), nausea (mild/moderate/severe) and pruritus (mild/moderate/severe).
Time Frame
Adverse events during treatment (0-24 hours) and final assessment within 24 hours of end of treatment
Title
Pain rating
Description
Pain rating will be assessed using a numeric rating scale (NRS, 0-10; 0= no pain, 10=worst imaginable pain) before treatment start, at every hour for the first 8 hours of treatment and every other hour thereafter. Worst pain at delivery will also be assessed.
Time Frame
During treatment (0-24 hours)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pregnant women in labor requesting epidural analgesia ASA group 1 and 2 0 or 1 previous births Must be at least 18 years of age. Singleton pregnancy Active labor Signed informed consent and expected cooperation of the patient Exclusion Criteria: Poor communication skills in norwegian or english Adverse reactions to local anesthetics or synthetic opioids Body height below 150 cm Gestational age below 37 weeks, 0 days Any contraindication to epidural catheter placement (e.g. patients with coagulopathy, infection in area etc) Pre-eclampsia Sound reason by the investigator to suspect patient non-compliance (e.g. with use of PCEA)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vegard Dahl, MD, Dr. Med.
Organizational Affiliation
University Hospital, Akershus
Official's Role
Principal Investigator
Facility Information:
Facility Name
Akershus UH
City
Lørenskog
State/Province
Akershus
ZIP/Postal Code
1478
Country
Norway

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No plan to share individual participant data.
Citations:
PubMed Identifier
23223119
Citation
George RB, Allen TK, Habib AS. Intermittent epidural bolus compared with continuous epidural infusions for labor analgesia: a systematic review and meta-analysis. Anesth Analg. 2013 Jan;116(1):133-44. doi: 10.1213/ANE.0b013e3182713b26. Epub 2012 Dec 7. Erratum In: Anesth Analg. 2013 Jun;116(6):1385.
Results Reference
background

Learn more about this trial

The Programmed Intermittent Epidural Bolus Adrenaline Study

We'll reach out to this number within 24 hrs